






192 Copyright ⓒ  2009 Korean Neurological Association
Print  ISSN 1738-6586 / On-line  ISSN 2005-5013
10.3988/jcn.2009.5.4.192 J Clin Neurol 2009;5:192-194   
 
A Novel PANK2 Mutation in a Patient with Atypical   
Pantothenate-Kinase-Associated Neurodegeneration  
Presenting with Adult-Onset Parkinsonism 
 
Joo-Hyun Seo, MD; Sook-Keun Song, MD; Phil Hyu Lee, MD, PhD 
Department of Neurology, Yonsei University College of Medicine, Seoul, Korea 
 
Received  March 5, 2009 
Revised  April 15, 2009 
Accepted  April 15, 2009 
 
Correspondence 
Phil Hyu Lee, MD, PhD 
Department of Neurology, 
Yonsei University   
College of Medicine,   
250 Seongsan-ro, Seodaemun-gu, 
Seoul 120-752, Korea 
Tel +82-2-2228-1608 
Fax +82-2-393-0705 
E-mail  phisland@chol.com   
 
BackgroundaaPantothenate-kinase-associated neurodegeneration (PKAN) is an autosomal re-
cessive neurodegenerative disorder that is characterized by progressive extrapyramidal signs, 
visual loss, and cognitive impairment. PKAN is caused by mutations in the pantothenate kinase 
gene (PANK2), which is located on chromosome 20p13 and encodes pantothenate kinase, the 
key regulatory enzyme in coenzyme-A biosynthesis. 
Case ReportaaIn this report we describe a case of atypical PKAN with a novel PANK2 muta-
tion, presenting with a 10-year history of postural tremor involving both hands. Upon neurolo-
gical examination, the patient’s face was masked and he spoke in a monotonous voice. The pa-
tient presented with mild bradykinesia and rigidity that involved all of the extremities. Hori-
zontal saccadic eye movements were slow and fragmented. Brain MRI revealed a typical “eye-
of-the-tiger” sign. A mutation analysis revealed three PANK2 mutations: two in exon 3 (Asp 
378Gly and Leu385CysfsX13) and one in exon 4 (Arg440Pro). 
ConclusionsaaParkinsonism is not an unusual presenting symptom in patients with atypical 
PKAN, and so it is important for physicians to consider PKAN in the differential diagnosis of 
patients presenting with young-onset parkinsonism.  J Clin Neurol  2009;5:192-194
 
Key Wordsaapantothenate-kinase-associated neurodegeneration, neurodegeneration with brain 





Pantothenate-kinase-associated neurodegeneration (PKAN), 
formerly called Hallervorden-Spatz syndrome, is an autoso-
mal recessive neurodegenerative disorder characterized by 
progressive extrapyramidal signs, visual loss, and cognitive 
impairment.
1 PKAN is caused by mutations in PANK2, which 
is a gene located on chromosome 20p13 and encodes panto-
thenate kinase, the key regulatory enzyme in coenzyme-A 
biosynthesis.
2 PKAN belongs to a group of neurodegenerative 
diseases that includes neurodegeneration with brain iron ac-
cumulation (NBIA), infantile neuroaxonal dystrophy, aceru-
loplasminemia, and neuroferritinopathy. Iron accumulation 
in the globus pallidus can be frequently detected by MRI in a 
characteristic pattern referred to as the “eye-of-the-tiger” sign.
3 
Two main phenotypes of PKAN have been reported: clas-
sical and atypical.
1 Patients with classical PKAN typically 
present in the first decade of life with severe extrapyramidal 
signs, progressing relentlessly and leading to independent 
walking disability within 10-15 years after onset. However, 
atypical PKAN cases show later onset, less severe extrapyra-
midal signs, and slower progression. Here we describe a pa-
tient with atypical PKAN presenting with adult-onset, slowly 




A 45-year-old man was admitted to our hospital because of a 
10-year history of tremor involving both hands. His past me-
dical history was unremarkable. There was no history of per-
inatal complications and he met normal developmental mil-
estones. From the age of 35 years, the patient began experi-
encing bilateral postural hand tremor. He also felt a mild 
slowness of speech. Symptoms worsened gradually over se-
veral years. At the age of 40 years he was unable to continue 
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three brothers and two sisters; the oldest brother also had 
mild hand tremors that did not prevent him performing the 
activities of daily living independently. 
Upon neurological examination, the patient had a masked 
face and spoke in a monotonous voice. He presented with 
mild bradykinesia and rigidity involving all of his extremi-
ties. Horizontal saccadic eye movements were slow and frag-
mented. Pursuit eye movements were unremarkable. Out-
stretching his arm elicited a postural hand tremor with a 
moderate amplitude and a frequency of 5-6 Hz. Tongue tre-
mor, which seemed to be grossly synchronous with hand 
tremor, was also observed. On walking, his gait velocity was 
slow with decreased arm swing on his right side. There were 
no motor or sensory abnormalities. Deep-tendon reflexes were 
normoactive and without the Babinski sign. Complete blood 
count, biochemical screening, erythrocyte sedimentation rate, 
C-reactive protein, and urine were normal. Serum ceruloplas-
min and copper concentrations were normal. The serologic 
test for human immunodeficiency virus and assays for anti-
nuclear antibodies were negative. Brain MRI revealed bilate-
ral and symmetric hypointensity with medial hyperintensity 
in the globus pallidus on fluid attenuation inversion recovery 
imaging. This feature was in accordance with the “eye-of-the-
tiger” sign (Fig. 1). 
A mutation analysis (Fig. 2), in which PCR sequencing was 
utilized to identify PANK2 mutations, revealed three muta-
tions: two in exon 3 (Asp378Gly and Leu385CysfsX13) and 
one in exon 4 (Arg440Pro) of the gene. An A-to-G change at 
nucleotide 1133 results in the substitution of aspartate for 
glycine at amino acid 378 (D378G), an insertion of threonine 
at nucleotides 1154-1155 results in a frameshift at amino 
acid 385 (L385fs), and a G-to-C change at nucleotide 1319 
results in the substitution of arginine for proline (R440P). 
Other members of his family did not consent to genetic test-
ing. There was no overt response of the patient’s parkinso-
nism to the introduction of L-dopa. However, his hand tre-
mor improved partially after treatment with pramipexole di-
hydrochloride (0.5 mg three times daily) and clonazepam 




Phenotypically, the present case is compatible with atypical 
PKAN in terms of adult onset, its slowly progressive nature, 
and its parkinsonian presentation. Several cases of NBIA 
that presented with adult-onset parkinsonism have been re-
ported in the literature, and in their series of patients with 
NBIA, Thomas et al.
4 reported that four out of ten patients 
with a PANK2 mutation initially presented with parkinso-
nism. Regarding the phenomenology of PKAN-associated 
movement disorders, patients with an early onset predomi-
nantly presented with dystonia, whereas adult-onset patients 
exhibited parkinsonism as the initial symptom. Although 
parkinsonism has frequently been observed in early-onset 
PKAN patients, other neurologic abnormalities of dystonia, 
pyramidal signs, and cognitive impairment were generally 
combined.
5,6 Accordingly, pure parkinsonism is not an unus-
ual presenting symptom of atypical PKAN.
4 
The genetic analysis revealed two PANK2 mutations in 
exon 3 (Asp378Gly and Leu385CysfsX13) and one in exon 













R=A and G 
S=G and C 
Fig. 2. PANK2 mutation analysis revealed three muta-
tions: a substitution at nucleotide 1133 (A>G) and inser-
tion of threonine at nucleotides 1154-1155 in exon 3,
and a substitution at nucleotide 1319 (G>C) in exon 4. 
Fig. 1. Axial fluid attenuation inversion recovery MRI showing low
signal intensity with a medial area of bilateral high signal intensity
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mutation found in PKAN.
7 However, L385fs and R440P are 
novel mutations that have not been reported previously. In-
sertion of threonine at nucleotides 1154-1155 in exon 3 re-
sults in a frameshift mutation with a premature termination 
of translation at amino acid 385. It may be a null allele that 
causes a loss of function. A novel substitution at nucleotide 
1319 in exon 4 replaces arginine in position 440 with proline. 
Arginine provides a positive hydrophilic charge with basic 
side chains, while proline is a cyclic amino acid that has a 
neutral hydrophobic charge. Therefore, it may be speculated 
that the arginine-to-proline substitution results in loss of the 
functional properties of the PANK2 protein. 
Regarding the association between PANK2 mutation and 
clinical phenotype, two loss-of-function alleles and residual 
enzymatic activity of PANK2 are known to significantly de-
termine the age of onset of the disease, but have a much 
weaker influence on the rate of disease progression.
6 Simi-
larly, Thomas et al.
4 suggested that patients with atypical 
PKAN were more likely to have mutations resulting in amino-
acid changes. Although we were unable to determine the en-
zymatic activity of PANK2 in our case, this compound hete-
rozygous mutation may have been responsible for the adult-
onset and delayed progressive nature of the disease. 
Mutations on both alleles of PANK2 are identified in about 
50% of patients with clinical features of PKAN, and in more 
than 98% of patients with radiographic features of the dise-
ase.
7 As mentioned previously, parkinsonism is not an un-
usual presenting symptom in patients with atypical PKAN, 
and it is important for physicians to consider PKAN in the 
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